Here are six things to know about the study.
1. Alaska Native people have high rates of colorectal cancer and limited access to screening.
2. The study examined 868 asymptomatic patients aged 40 to 85 years undergoing screening or surveillance colonoscopy.
3. Of these patients, 661 completed the study. The researchers found stool DNA testing was superior to FMT in the screening group; screening-relevant colorectal neoplasia detection was 50 percent and 31 percent, respectively.
4. Specificities for stool DNA testing were 93 percent and 96 percent for FIT.
5. The study authors concluded stool DNA testing had high sensitivity for cancer and larger polyps, though FIT had slightly higher specificity.
6. The authors suggest stool DNA testing has the potential to be used to expand CRC screening and reduce CRC incidence in underserved areas.
More articles on gastroenterology:
Lovelace Medical Group adds Dr. Julie Farrer: 3 things to know
Global endoscopy market to reach $9.7B by 2021: 5 key trends
The biggest challenges for GI in 2016: 3 gastroenterologists weigh in
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.